...
首页> 外文期刊>International immunopharmacology >Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion.
【24h】

Hematopoietic cytokine-induced transcriptional regulation and Notch signaling as modulators of MDSC expansion.

机译:造血细胞因子诱导的转录调节和Notch信号作为MDSC扩展的调节剂。

获取原文
获取原文并翻译 | 示例

摘要

Hematopoietic stem cells (HSCs) differentiate into mature lineage restricted blood cells under the influence of a complex network of hematopoietic cytokines, cytokine-mediated transcriptional regulators, and manifold intercellular signaling pathways. The classical model of hematopoiesis proposes that progenitor cells undergo a dichotomous branching into myelo-erythroid and lymphoid lineages. Nonetheless, erythroid and lymphoid restricted progenitors retain their myeloid potential, supporting the existence of an alternative 'myeloid-based' mechanism of hematopoiesis. In this case, abnormal pathology is capable of dysregulating hematopoiesis in favor of myelopoiesis. The accumulation of immature CD11b+Gr-1+ myeloid-derived suppressor cells (MDSCs) has been shown to correlate with the presence of several hematopoietic cytokines, transcription factors and signaling pathways, lending support to this hypothesis. Although the negative role of MDSCs in cancer development is firmly established, it is now understood that MDSCs can exert a paradoxical, positive effect on transplantation, autoimmunity, and sepsis. Our conflicted understanding of MDSC function and the complexity of hematopoietic cytokine signaling underscores the need to elucidate molecular pathways of MDSC expansion for the development of novel MDSC-based therapeutics.
机译:造血干细胞(HSC)在复杂的造血细胞因子,细胞因子介导的转录调节因子和多种细胞间信号传导途径的影响下,分化为成熟谱系受限的血细胞。造血的经典模型提出,祖细胞经历二叉状分支进入骨髓红系和淋巴样谱系。尽管如此,红系和淋巴样受限制的祖细胞仍保留了其髓样潜能,支持了另一种基于“髓样”的造血机制的存在。在这种情况下,异常病理能够使造血功能失调,有利于骨髓造血。研究表明,未成熟的CD11b + Gr-1 +髓样抑制细胞(MDSCs)的积累与几种造血细胞因子,转录因子和信号通路的存在相关,这为这一假设提供了支持。尽管已经牢固确立了MDSCs在癌症发展中的负面作用,但现在已经知道MDSCs可以对移植,自身免疫和败血症产生反常的积极作用。我们对MDSC功能的理解和造血细胞因子信号传导的复杂性相互矛盾,这凸显了为开发基于MDSC的新型治疗药物阐明MDSC扩展的分子途径的需要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号